Part III – The Battleground: China’s Biotech Shift in Cardiometabolics and the GLP-1 Gravity Well

Few areas of medicine are pulling in as much money, policy focus, and industry competition as cardiometabolic disease. The diabetes and obesity market, already reshaped by GLP-1 therapies, is heading for another inflection point: China’s 2026 semaglutide patent expiry. That single event is catalyzing a rush of local players—some working on biosimilars and generics (Jiuyuan/Huadong, Livzon), others betting on new combinations or next-gen molecules like Innovent’s recently approved mazdutide. The result is likely to be faster uptake and sharper pricing at home, with knock-on effects abroad.

China’s Patent Expiry Turns Cardiometabolic Disease Into the Next Global Battleground

What makes this moment different is how China’s regulatory and market environment has evolved. Clinical approvals now move faster, trial oversight is more predictable, and government procurement drives down costs. That creates a two-sided pressure: rapid entry for low-cost generics on one end, and strong incentives to push bold first-in-class therapies on the other. Together, these forces suggest China could broaden access to GLP-1s while simultaneously raising the bar for innovation.

For investors and global pharmas, the implications go well beyond China’s borders. If GLP-1 drugs and next-gen incretins are sold at deep discounts in China, Western payers may seize on those benchmarks to demand lower prices from incumbents like Novo Nordisk and Eli Lilly. In other words, China’s market could become a reference point that tightens margins worldwide.

That feedback loop shows why cardiometabolic disease is fast becoming biotech’s new gravity well. It is drawing in not just Chinese innovators and generics makers, but also shaping how multinationals balance portfolios, strike licensing deals, and place long-term pipeline bets. With obesity and metabolic disorders surging globally—and healthcare systems prioritizing solutions—the sector now stands as the next big battleground after oncology. 

Therapeutic Fronts: Where China Could Reset Global Benchmarks

Oncology continues to set the pace, anchoring China’s global biotech integration through incubators in Shanghai and Beijing and cross-border licensing deals that validate local discovery platforms. These partnerships confirm oncology as the proving ground for large, multi-asset collaborations.

But, cardiometabolic pulls in capital. The upcoming 2026 semaglutide patent expiry is catalyzing a wave of activity across China’s biopharma sector. Hangzhou Jiuyuan Gene Engineering, a Huadong Medicine subsidiary, has filed for approval of Jiyoutai, a semaglutide biosimilar for type 2 diabetes, after completing a Phase III trial in 476 patients directly comparing it with Ozempic. 

Similarly, Livzon Pharmaceutical Group has also advanced its own semaglutide biosimilar through Phase III and submitted it for regulatory review. Alongside the biosimilar push, Innovent Biologics has won NMPA approval for mazdutide, the first dual glucagon/GLP-1 receptor agonist in China, to be used for chronic weight management in overweight or obese adults (PR Newswire). Analysts note that mazdutide represents a next-generation incretin alternative now entering the market. With nearly 148 million adults in China living with diabetes, this mix of generics, biosimilars, and new incretin classes is setting up intense pricing competition and rapid uptake. The shift has global consequences—earlier generic entry and lower GLP-1 prices in China could feed into Western payer negotiations, tightening reference pricing and challenging revenue models for obesity and diabetes therapies worldwide.

So what this means is that, together, these fronts signal that China is not just supplying molecules but shaping how therapeutic markets are priced and prioritized—forcing global companies to adjust portfolio strategies, pricing assumptions, and competitive timelines.

Market Share Dynamics Inside China

China’s semaglutide patent cliff creates a massive commercial opening, and local firms are preparing aggressively to seize share. According to GlobalData, 16 Chinese companies are developing generic semaglutide across various stages (2 in pre-registration, 10 in Phase III, 2 in Phase II, and 2 in Phase I), with Huisheng Biopharmaceutical and CSPC in pre-registration. United Laboratories, Huadong Medicine, and Qilu Pharmaceutical are pushing Phase III programs, while others advance earlier candidates, all targeting rapid launches in 2026.

Meanwhile, China’s obesity and diabetes burden keeps expanding. Diagnosed diabetes cases are projected to surpass 63 million by 2028, while obesity prevalence will exceed 165 million by 2031. This ensures sustained demand for effective, lower-cost GLP-1 therapies. Analysts expect intense price competition once generics enter, accelerating uptake and broadening access beyond wealthy, urban patients. As a result, Chinese firms are positioned not just as participants, but as market shapers driving down costs and expanding supply.

China’s Patent Cliff Isn’t Just Local—It’s Everyone’s Reality

However, patent expiries in 2026 extend beyond China. Canada, India, and Brazil will also see generic semaglutide entry, creating parallel opportunities. Indian firms like Dr Reddy’s and Biocon are already advancing biosimilars and striking supply deals in Brazil and beyond. Brazil’s regulator ANVISA has received multiple applications, signaling competitive entry in Latin America’s growing diabetes market.

At the same time, Western markets remain protected until 2031–2032, allowing branded incumbents like Novo Nordisk and Lilly to hold share longer. Still, low-cost generics in Asia and Latin America could shift global reference pricing and influence payer negotiations in Europe and the U.S. IQVIA estimates that one in three people with obesity will live in countries with off-patent semaglutide by 2026. Therefore, global GLP-1 use could expand dramatically, pushing therapies into middle-income markets once excluded by high costs.

Strategic Implications: From Local Expiry to Global Shift

The coming wave of generics expands supply, lowers cost, and increases global access to GLP-1 therapies. Analysts are revising sugar consumption forecasts downward, reflecting potential behavioral shifts as GLP-1 use widens. Multinationals face thinner margins, new competitors, and portfolio rebalancing as China and India set new benchmarks. Ultimately, China’s semaglutide expiry marks not only a local market event but also a global turning point for cardiometabolic care.

Author

Bernice Lottering